Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
GBT Global Blood Therapeutics Inc. daily Stock Chart
GBT [NASD]
Global Blood Therapeutics Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-2.47 Insider Own3.20% Shs Outstand44.22M Perf Week-2.88%
Market Cap1.42B Forward P/E- EPS next Y-2.91 Insider Trans-9.09% Shs Float41.71M Perf Month11.89%
Income-95.40M PEG- EPS next Q-0.61 Inst Own14.94% Short Float13.95% Perf Quarter6.84%
Sales- P/S- EPS this Y37.10% Inst Trans2.55% Short Ratio7.43 Perf Half Y10.34%
Book/sh6.54 P/B4.89 EPS next Y-19.30% ROA-36.50% Target Price57.09 Perf Year77.29%
Cash/sh5.20 P/C6.16 EPS next 5Y37.00% ROE-38.90% 52W Range13.35 - 41.15 Perf YTD121.45%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-22.24% Beta-
Dividend %- Quick Ratio13.70 Sales past 5Y- Gross Margin- 52W Low139.70% ATR1.46
Employees95 Current Ratio13.70 Sales Q/Q- Oper. Margin- RSI (14)57.92 Volatility3.79% 5.03%
OptionableYes Debt/Eq0.00 EPS Q/Q4.70% Profit Margin- Rel Volume1.20 Prev Close32.45
ShortableYes LT Debt/Eq0.00 EarningsNov 06 AMC Payout- Avg Volume783.36K Price32.00
Recom1.80 SMA203.15% SMA509.62% SMA20014.03% Volume930,785 Change-1.39%
Sep-21-17Initiated Needham Buy $51
Aug-08-17Reiterated JP Morgan Overweight $44 → $46
Apr-18-17Initiated SunTrust Buy $56
Mar-21-17Resumed Wedbush Outperform $73
Mar-16-17Initiated Cantor Fitzgerald Overweight $61
Mar-02-17Initiated Instinet Buy $50
Jan-04-17Initiated JP Morgan Overweight
Nov-01-16Initiated ROTH Capital Buy $47
Oct-25-16Reiterated Wedbush Outperform $66 → $73
Sep-30-16Initiated Wells Fargo Outperform
Mar-02-16Reiterated Wedbush Outperform $94 → $66
Sep-08-15Initiated Wedbush Outperform
Sep-08-15Initiated Morgan Stanley Overweight $67
Sep-08-15Initiated Goldman Neutral $44
Oct-11-17 08:00AM  Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype GlobeNewswire
Oct-05-17 03:00AM  Global Blood Therapeutic Earns Relative Strength Rating Upgrade Investor's Business Daily
Oct-04-17 01:08PM  Steven Cohen Doubles Down on Sickle Cell Disease Therapeutics Company Global Blood GuruFocus.com +8.92%
Oct-03-17 08:00AM  Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings in October GlobeNewswire
Sep-26-17 04:05PM  Global Blood Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Sep-21-17 10:21AM  One Thing To Consider Before Buying Global Blood Therapeutics Inc (GBT) Simply Wall St. -5.07%
Sep-14-17 03:00AM  Global Blood Therapeutic Sees IBD RS Rating Climb To 71 Investor's Business Daily
Sep-06-17 08:00AM  Global Blood Therapeutics To Convene Sickle Cell Disease Influencers at Annual Sickle Cell Disease (SCD) Therapeutics Conference GlobeNewswire
Sep-05-17 08:00AM  Global Blood Therapeutics Receives Rare Pediatric Disease Designation from FDA for GBT440 for Treatment of Sickle Cell Disease (SCD) GlobeNewswire -6.27%
Aug-30-17 04:05PM  Global Blood Therapeutics Announces Upcoming Participation in Multiple Investor Conferences in September GlobeNewswire
Aug-09-17 04:05PM  Global Blood Therapeutics Announces Participation at the 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-07-17 11:57PM  Global Blood reports 2Q loss Associated Press
04:05PM  Global Blood Therapeutics Reports Recent Business Progress and Provides Second Quarter 2017 Financial Results GlobeNewswire
Jul-26-17 04:05PM  Global Blood Therapeutics Announces New Employment Inducement Grants GlobeNewswire
Jul-10-17 08:00AM  Global Blood Therapeutics Expands Ongoing Phase 2a HOPE-KIDS 1 Study into Younger Pediatric Population GlobeNewswire
Jul-03-17 08:31AM  Implied Volatility Surging for Global Blood Therapeutics (GBT) Stock Options Zacks +5.30%
Jun-28-17 09:29AM  Global Blood Shares Pop on Priority Designation; Kite Pharma Rises on Patent News: Biotech Movers TheStreet.com +9.09%
08:31AM  Global Blood Therapeutics stock surges 5% on eligibility for European priority drug program MarketWatch
08:00AM  Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD) GlobeNewswire
Jun-23-17 02:30AM  Global Blood Therapeutics Announces New Data Supporting Ongoing Clinical Development of GBT440 in Adolescents with Sickle Cell Disease GlobeNewswire
Jun-06-17 04:05PM  Global Blood Therapeutics Announces Participation at the Goldman Sachs 38th Annual Global Healthcare Conference GlobeNewswire
May-18-17 04:00PM  Global Blood Therapeutics Announces Upcoming Presentation of GBT440 Data in Adolescents with Sickle Cell Disease at European Hematology Associations 22nd Congress GlobeNewswire
May-01-17 04:10PM  Global Blood reports 1Q loss Associated Press +6.22%
04:05PM  Global Blood Therapeutics Reports Recent Business Progress and Provides First Quarter 2017 Financial Results GlobeNewswire
Mar-30-17 04:06PM  GLOBAL BLOOD THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
10:33AM  5 Top Performing Stocks of the Best ETF of Q1 Investopedia
10:33AM  5 Top Performing Stocks of the Best ETF of Q1 at Investopedia
Mar-29-17 04:05PM  Global Blood Therapeutics to Present at the 16th Annual Needham Healthcare Conference GlobeNewswire
Mar-22-17 05:13PM  GLOBAL BLOOD THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements
01:06PM  Market Is Home on the Range Again TheStreet.com
01:06PM  Market Is Home on the Range Again
Mar-20-17 09:30AM  Global Blood Therapeutics' Acquisition Value Could Be At Least $3 Billion Benzinga
Mar-17-17 01:04PM  GLOBAL BLOOD THERAPEUTICS, INC. Financials
Mar-16-17 05:35PM  5 Stocks The Best Performing Hedge Funds Are Piling Into Insider Monkey
05:35PM  5 Stocks The Best Performing Hedge Funds Are Piling Into at Insider Monkey
07:42AM  Global Blood Therapeutics Demonstrates 'Compelling Potential' In Sickle Cell Treatment Benzinga
05:46AM  Coverage initiated on Global Blood Therapeutics by Cantor Fitzgerald
Mar-13-17 05:52PM  Global Blood reports 4Q loss
05:14PM  Market Takes 'National Napping Day' Seriously TheStreet.com
05:14PM  Market Takes 'National Napping Day' Seriously
04:07PM  GLOBAL BLOOD THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen
04:05PM  Global Blood Therapeutics Reports Recent Business Progress and Fourth Quarter and Year-End 2016 Financial Results GlobeNewswire
11:25AM  Biotech Leads the Way Again Today
10:36AM  These 3 Stocks Have Doubled Investors' Money at Motley Fool
Mar-10-17 04:30PM  Late Market Rally but No Bounce for Bulls
02:33PM  Adam Feuerstein Weighs In On Novo-GBT Rumors, Undue Sarepta Volatility, Unprofitable Business Of Curing Disease
05:40AM  Heres Our Take On The Global Blood Therapeutics Inc (GBT) Rumors at Insider Monkey
Mar-09-17 05:14PM  Biotech Reporter Adam Feuerstein Will Be On Benzinga's PreMarket Prep Friday Morning +5.55%
11:17AM  Novo Nordisk in Talks to Buy Global Blood Therapeutics (NVO,GBT) at Investopedia
10:47AM  Market Set Up for Oversold Bounce
10:10AM  Company News for March 09, 2017
07:00AM  7 Stocks Trending Up With Monster Volume
Mar-08-17 05:39PM  Global Blood Therapeutics Shares Jump on Report It Was Approached by Novo Nordisk +21.02%
04:34PM  Why H&R Block, PPG Industries, and Global Blood Therapeutics Jumped Today at Motley Fool
04:17PM  Why Global Blood Therapeutics Rocketed Higher Today at Motley Fool
01:34PM  Is This a Market Top or Just Consolidation?
11:49AM  Global Blood Therapeutics Stock Surging on Nordisk Bid Speculation
11:11AM  Global Blood Said to Mull Sale After Receiving Takeover Interest
Mar-03-17 11:25AM  Ted Love's quest for a new way to treat sickle cell disease BioFlash podcast at bizjournals.com
Mar-02-17 11:15AM  Shark Bites: Market Taking a Break, but Probably Not for Long -9.08%
11:15AM  Market Taking a Break, but Probably Not for Long
08:40AM  Global Blood Therapeutics (GBT) in Focus: Stock Jumps 6.8%
Mar-01-17 04:05PM  Global Blood Therapeutics Announces Participation at Two Upcoming Investor Conferences in March GlobeNewswire +6.82%
Feb-27-17 04:40PM  GLOBAL BLOOD THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:05PM  Global Blood Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares GlobeNewswire
Feb-23-17 10:47AM  Markets Are Selling the Mnuchin News +7.58%
06:00AM  These Small Biotechs Are Poised to Go Higher at Investopedia
Feb-22-17 05:31PM  GLOBAL BLOOD THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financi -14.39%
04:55PM  Why Newfield Exploration, Global Blood Therapeutics, and Nautilus Slumped Today at Motley Fool
12:10PM  Here's Why Global Blood Therapeutics Inc. Is Tanking at Motley Fool
08:00AM  Global Blood Therapeutics Prices a $125.0 Million Upsized Common Stock Public Offering GlobeNewswire
Feb-21-17 04:01PM  Global Blood Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire +5.95%
10:54AM  Trading in a Rising Market Simply Isn't as Simple as It May Seem at TheStreet
Feb-18-17 01:26AM  [$$] Why Biotech Looks Like a Good Bet in 2017 at Barrons.com
Feb-17-17 08:06AM  GLOBAL BLOOD THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +7.82%
Feb-16-17 04:05PM  Global Blood Therapeutics Announces Initiation of Phase 1 Trial to Evaluate the Physiologic Effects of GBT440 in Healthy Volunteers Under Hypoxemic Conditions GlobeNewswire +6.85%
Feb-14-17 08:30AM  Global Blood Therapeutics Announces Publication of Paper Describing Discovery of GBT440 in ACS Medicinal Chemistry Letters GlobeNewswire +9.27%
Feb-13-17 10:36AM  Fear of Missing Out Is Building
Jan-20-17 04:06PM  GLOBAL BLOOD THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Jan-18-17 08:30AM  Global Blood Therapeutics Announces Enrollment of First Patient in Phase 3 HOPE Study in Sickle Cell Disease GlobeNewswire
Jan-05-17 07:21AM  Rev's Forum: The Fed Isn't Convinced the Trump Rally Is Justified
Jan-04-17 10:56AM  Trying to Knock Out Some Individual Trades, but it Is not Easy +10.84%
Jan-03-17 04:05PM  Global Blood Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-23-16 11:42AM  Shark Bites: We Knew Today Would Be Slow, but Come On
Dec-16-16 08:30AM  Global Blood Therapeutics Added to NASDAQ Biotechnology Index GlobeNewswire
Dec-05-16 01:11PM  Blood Work: A Few Biotech Thoughts From Sunny San Diego and the ASH 2016 Meeting -9.69%
01:03PM  GLOBAL BLOOD THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
01:01PM  Global Blood Therapeutics Announces New Details on its Novel Patient Reported Outcomes (PRO) Tool to be used in Phase 3 HOPE Study GlobeNewswire
03:53AM  Hedge Funds Are Dumping Nanometrics Incorporated (NANO) at Insider Monkey
Dec-04-16 12:01PM  Global Blood Therapeutics Announces New Long-Term Clinical Data from Ongoing Phase 1/2 Trial of GBT440 in Sickle Cell Disease at ASH GlobeNewswire
Nov-30-16 04:05PM  Global Blood Therapeutics Announces Upcoming Investor Webcast to Review GBT440 Data Being Presented at ASH that Support Sickle Cell Disease Program GlobeNewswire
09:00AM  Global Blood Therapeutics Announces GBT440 Granted Orphan Drug Designation in Europe for Treatment of Sickle Cell Disease GlobeNewswire
Nov-28-16 02:18PM  Global Blood Therapeutics, Inc. :GBT-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016
09:06AM  GLOBAL BLOOD THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:00AM  Global Blood Therapeutics Announces Initiation of Phase 2a Trial of GBT440 in Idiopathic Pulmonary Fibrosis (IPF) GlobeNewswire
Nov-10-16 05:15PM  GLOBAL BLOOD THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers +7.14%
07:07AM  Q3 2016 Global Blood Therapeutics Inc Earnings Release - After Market Close
Nov-09-16 05:49PM  Global Blood reports 3Q loss +7.69%
04:06PM  GLOBAL BLOOD THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statemen
04:05PM  Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2016 Financial Results GlobeNewswire
Global Blood Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics to treat grievous blood-based disorders. Its lead product candidate is GBT440, a hemoglobin modifier that binds to hemoglobin molecules, which is in Phase 3 clinical trial for the treatment of sickle cell disease (SCD) in adult and adolescent patients, as well as evaluates the safety and pharmacokinetics of single and multiple doses of GBT440 on adolescent patients with SCD. The company is also involved in conducting Phase 2 clinical trials of GBT440 for the treatment of idiopathic pulmonary fibrosis, which is a hypoxemic pulmonary disorder; and other pre-clinical research and development activities. Global Blood Therapeutics Inc. was founded in 2011 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Choi JungSee RemarksOct 17Option Exercise3.401,4004,760139,855Oct 18 06:19 PM
Choi JungSee RemarksOct 17Sale32.653,00097,950138,455Oct 18 06:19 PM
Choi JungSee RemarksSep 29Option Exercise3.401,4004,760141,455Oct 02 05:27 PM
Choi JungSee RemarksSep 29Sale30.003,00090,000140,055Oct 02 05:27 PM
Choi JungSee RemarksAug 31Option Exercise3.401,4004,760143,055Sep 05 06:36 PM
Radovich PeterSee RemarksAug 31Sale30.002,41072,3002,684Sep 05 06:37 PM
Choi JungSee RemarksAug 31Sale30.003,00090,000141,655Sep 05 06:36 PM
Sham HingSee RemarksAug 02Option Exercise0.4921,42810,50081,504Aug 03 04:36 PM
PATRICK DEVAL LDirectorJul 25Option Exercise11.9727,053323,73027,053Jul 27 05:49 PM
PATRICK DEVAL LDirectorJul 25Sale29.6927,053803,2040Jul 27 05:49 PM
Choi JungSee RemarksJul 21Option Exercise3.401,4004,760144,655Jul 25 07:02 PM
Choi JungSee RemarksJul 21Sale30.003,00090,000143,255Jul 25 07:02 PM
HOMCY CHARLES JDirectorJun 02Sale27.2081,7012,222,124137,728Jun 22 09:38 PM
HOMCY CHARLES JDirectorJun 01Sale26.5818,299486,345219,429Jun 22 09:38 PM
TEPPER ROBERT I10% OwnerApr 06Sale33.2331,2251,037,576229,773Apr 10 05:30 PM
Third Rock Ventures II, L.P.10% OwnerMar 02Sale25.542,045,29452,245,476146,208Mar 06 07:47 PM
STARR KEVIN P10% OwnerDec 16Sale16.00108,9551,743,34582,544Dec 20 05:46 PM
Third Rock Ventures II, L.P.10% OwnerNov 14Sale19.362,000,00038,720,0001,285,713Nov 16 04:12 PM
open in yahoo | open in reuters | open in google